![Philip Barach](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Philip Barach
Algemeen Directeur bij Équilibre BioPharmaceuticals Corp.
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Steven N. Gordon | M | 56 |
Équilibre BioPharmaceuticals Corp.
![]() Équilibre BioPharmaceuticals Corp. BiotechnologyHealth Technology Équilibre BioPharmaceuticals Corp. is an innovative biopharmaceutical company based in New York, NY. The company focuses on identifying and developing high-potential drugs for patients who are treatment resistant or unresponsive to other existing medications. The company's approach is to leverage their biopharmaceutical industry expertise to further expand their portfolio of product opportunities. The company is a patient-focused and science-minded company determined to have best and first-in-class therapeutics. The CEO of the company is Philip Barach. | - |
Francois Maisonrouge | M | - |
Équilibre BioPharmaceuticals Corp.
![]() Équilibre BioPharmaceuticals Corp. BiotechnologyHealth Technology Équilibre BioPharmaceuticals Corp. is an innovative biopharmaceutical company based in New York, NY. The company focuses on identifying and developing high-potential drugs for patients who are treatment resistant or unresponsive to other existing medications. The company's approach is to leverage their biopharmaceutical industry expertise to further expand their portfolio of product opportunities. The company is a patient-focused and science-minded company determined to have best and first-in-class therapeutics. The CEO of the company is Philip Barach. | - |
Peter Simon | M | 75 |
Équilibre BioPharmaceuticals Corp.
![]() Équilibre BioPharmaceuticals Corp. BiotechnologyHealth Technology Équilibre BioPharmaceuticals Corp. is an innovative biopharmaceutical company based in New York, NY. The company focuses on identifying and developing high-potential drugs for patients who are treatment resistant or unresponsive to other existing medications. The company's approach is to leverage their biopharmaceutical industry expertise to further expand their portfolio of product opportunities. The company is a patient-focused and science-minded company determined to have best and first-in-class therapeutics. The CEO of the company is Philip Barach. | - |
David Freidman | M | - |
Équilibre BioPharmaceuticals Corp.
![]() Équilibre BioPharmaceuticals Corp. BiotechnologyHealth Technology Équilibre BioPharmaceuticals Corp. is an innovative biopharmaceutical company based in New York, NY. The company focuses on identifying and developing high-potential drugs for patients who are treatment resistant or unresponsive to other existing medications. The company's approach is to leverage their biopharmaceutical industry expertise to further expand their portfolio of product opportunities. The company is a patient-focused and science-minded company determined to have best and first-in-class therapeutics. The CEO of the company is Philip Barach. | - |
Steven N. Gordon | M | - |
Équilibre BioPharmaceuticals Corp.
![]() Équilibre BioPharmaceuticals Corp. BiotechnologyHealth Technology Équilibre BioPharmaceuticals Corp. is an innovative biopharmaceutical company based in New York, NY. The company focuses on identifying and developing high-potential drugs for patients who are treatment resistant or unresponsive to other existing medications. The company's approach is to leverage their biopharmaceutical industry expertise to further expand their portfolio of product opportunities. The company is a patient-focused and science-minded company determined to have best and first-in-class therapeutics. The CEO of the company is Philip Barach. | - |
Christina M. Ramirez | M | - |
Équilibre BioPharmaceuticals Corp.
![]() Équilibre BioPharmaceuticals Corp. BiotechnologyHealth Technology Équilibre BioPharmaceuticals Corp. is an innovative biopharmaceutical company based in New York, NY. The company focuses on identifying and developing high-potential drugs for patients who are treatment resistant or unresponsive to other existing medications. The company's approach is to leverage their biopharmaceutical industry expertise to further expand their portfolio of product opportunities. The company is a patient-focused and science-minded company determined to have best and first-in-class therapeutics. The CEO of the company is Philip Barach. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 6 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Philip Barach
- Persoonlijk netwerk